Entrada Therapeutics, INC Form 4 insider transactions

Kory James Wentworth, CFO of Entrada Therapeutics, sold 4,086 shares of common stock at a weighted average price of $12.3067 on March 6, 2024, according to a Form 4 filing with the SEC.

Nathan Dowden, President & COO of Entrada Therapeutics, sold 1,826 shares of common stock at a weighted average price of $12.3213, executed under a pre-arranged 10b5-1 trading plan.

Entrada Therapeutics CEO Dipal Doshi reports acquisition of restricted stock units and stock options, along with sales to cover tax obligations.

Kory James Wentworth, CFO of Entrada Therapeutics, reports acquisition of restricted stock units and stock options, along with sales to cover tax obligations.

Nathan Dowden, President & COO of Entrada Therapeutics, reports the acquisition and disposal of common stock and stock options, including grants of restricted stock units and sales to cover tax obligations.

Natarajan Sethuraman, Chief Scientific Officer of Entrada Therapeutics, reports the acquisition of restricted stock units and stock options, along with sales of common stock to cover tax obligations.